Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial)

被引：0
|
作者：
McClanahan, F. [1 ]
Hielscher, T. [2 ]
Rieger, M. [1 ]
Hensel, M. [3 ]
Bentz, M. [4 ]
Schmidt-Wolf, I [5 ]
Kaebisch, A. [6 ]
Salwender, H. [7 ]
Duerk, H. [8 ]
Staiger, H. [9 ]
Mandel, T. [10 ]
Neben, K. [1 ]
Hillengass, J. [1 ]
Ho, A. D. [1 ]
Witzens-Harig, M. [1 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[3] Onkol Schwerpunkt Praxis, Mannheim, Germany
[4] Stadtkrankenhaus Karlsruhe, Karlsruhe, Germany
[5] Univ Hosp Bonn, Bonn, Germany
[6] Facharztpraxis Innere Med, Giessen, Germany
[7] Asklepios Klin Altona, Hamburg, Germany
[8] St Marien Krankenhaus, Hamm, Germany
[9] Klinikum Mittelbaden, Baden Baden, Germany
[10] SLK Klin Heilbronn, Bad Friedrichshall, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 37 条
  • [21] Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup
    Kreissl, S.
    Goergen, H.
    Kobe, C.
    Fuchs, M.
    Greil, R.
    Huettmann, A.
    Meissner, J.
    Feuring-Buske, M.
    Bentz, M.
    Dierlamm, J.
    Kuehnhardt, D.
    Lohri, A.
    Novak, U.
    Eichenauer, D.
    Eich, H.
    Baues, C.
    Stein, H.
    Diehl, V.
    Kuhnert, G.
    Dietlein, M.
    Engert, A.
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 201 - 201
  • [22] TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP
    Borchmann, P.
    Goergen, H.
    Kobe, C.
    Fuchs, M.
    Greil, R.
    Zijlstra, J. M.
    Huettmann, A.
    Markova, J.
    Meissner, J.
    Feuring-Buske, M.
    Bentz, M.
    Dierlamm, J.
    Kuehnhardt, D.
    Lohri, A.
    Novak, U.
    Eichenauer, D.
    Eich, H.
    Baues, C.
    Stein, H.
    Diehl, V.
    Kuhnert, G.
    Dietlein, M.
    Engert, A.
    HAEMATOLOGICA, 2017, 102 : 24 - +
  • [23] THERAPEUTIC COMPLIANCE OF 6 CYCLES OF DOSE-DENSE IMMUNOCHEMOTHERAPY, R-CHOP-14 PLUS PEGFILGRASTIM, IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). PRELIMINARY RESULTS OF A PROSPECTIVE SPANISH TRIAL
    Gonzalez-Barca, E.
    Canales, M.
    Salar, A.
    Vidal, M. J.
    Ferrer, S.
    Bargay, J.
    Grande, C.
    Oriol, A.
    Garcia, J.
    Gardella, S.
    Lopez, A.
    Tomas, F. J.
    Briones, J.
    Caballero, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 308 - 308
  • [24] Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group
    Kobe, C.
    Goergen, H.
    Fuchs, M.
    Eich, H. T.
    Baues, C.
    Diehl, V.
    Kuhnert, G.
    Drzezga, A.
    Dietlein, M.
    Engert, A.
    Borchmann, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S312 - S312
  • [25] Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)
    Conte, P. F.
    Favalli, G.
    Gadducci, A.
    Katsaros, D.
    Panici, P. L. Benedetti
    Carpi, A.
    Scambia, G.
    Ballardini, M.
    Nanni, O.
    Pecorelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA
    Poeschel, Viola
    Held, Gerhard
    Ziepert, Marita
    Altmann, Bettina
    Witzens-Harig, Mathias
    Holte, Harald
    Thurner, Lorenz
    Viardot, Andreas
    Borchmann, Peter
    Kanz, Lothar
    Keller, Ulrich
    Schmidt, Christian
    Mahlberg, Rolf
    Metzner, Bernd
    Marks, Reinhard
    Hoeffkes, Heinz-Gert
    Christofyllakis, Konstantinos
    Amam, Josif
    Berdel, Christian
    Stilgenbauer, Stephan
    Schmitz, Norbert
    Truemper, Lorenz
    Murawski, Niels
    Loeffler, Markus
    Pfreundschuh, Michael
    BLOOD, 2018, 132
  • [27] Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.
    Iveson, Timothy
    Kerr, Rachel
    Saunders, Mark P.
    Hollander, Niels Henrik
    Tabernero, Josep
    Haydon, Andrew Mark
    Glimelius, Bengt
    Harkin, Andrea
    Scudder, Claire
    Boyd, Kathleen
    Waterston, Ashita Marie
    Medley, Louise C.
    Wilson, Charles
    Ellis, Richard
    Essapen, Sharadah
    Dhadda, Amandeep Singh
    Harrison, Mark
    Falk, Stephen
    Raouf, Sherif
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Pfreundschuh, Michael
    Kuhnt, Evelyn
    Truemper, Lorenz
    Osterborg, Anders
    Trneny, Marek
    Shepherd, Lois
    Gill, Devinder S.
    Walewski, Jan
    Pettengell, Ruth
    Jaeger, Ulrich
    Zinzani, Pier-Luigi
    Shpilberg, Ofer
    Kvaloy, Stein
    Brown, Peter de Nully
    Stahel, Rolf
    Milpied, Noel
    Lopez-Guillermo, Armando
    Poeschel, Viola
    Grass, Sandra
    Loeffler, Markus
    Murawski, Niels
    LANCET ONCOLOGY, 2011, 12 (11): : 1013 - 1022
  • [29] The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial
    Xinxin Wang
    Shuo Li
    Yihong Sun
    Kai Li
    Xian Shen
    Yingwei Xue
    Pin Liang
    Guoli Li
    Luchuan Chen
    Qun Zhao
    Guoxin Li
    Weihua Fu
    Han Liang
    Hairong Xin
    Jian Suo
    Xuedong Fang
    Zhichao Zheng
    Zekuan Xu
    Huanqiu Chen
    Yanbing Zhou
    Yulong He
    Hua Huang
    Linghua Zhu
    Kun Yang
    Jiafu Ji
    Yingjiang Ye
    Zhongtao Zhang
    Fei Li
    Xin Wang
    Yantao Tian
    Sungsoo Park
    Lin Chen
    BMC Cancer, 21
  • [30] The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial
    Wang, Xinxin
    Li, Shuo
    Sun, Yihong
    Li, Kai
    Shen, Xian
    Xue, Yingwei
    Liang, Pin
    Li, Guoli
    Chen, Luchuan
    Zhao, Qun
    Li, Guoxin
    Fu, Weihua
    Liang, Han
    Xin, Hairong
    Suo, Jian
    Fang, Xuedong
    Zheng, Zhichao
    Xu, Zekuan
    Chen, Huanqiu
    Zhou, Yanbing
    He, Yulong
    Huang, Hua
    Zhu, Linghua
    Yang, Kun
    Ji, Jiafu
    Ye, Yingjiang
    Zhang, Zhongtao
    Li, Fei
    Wang, Xin
    Tian, Yantao
    Park, Sungsoo
    Chen, Lin
    BMC CANCER, 2021, 21 (01)
1234